If you have spent any time in the longevity corner of the internet, you have met NAD+ — the molecule that is supposedly going to reverse your biological clock. Influencers take it. Clinics infuse it. Supplement brands sell its "boosters" by the truckload. But strip away the marketing and there is a genuinely fascinating piece of cell biology underneath. NAD+ really is one of the most important molecules in your body, it really does decline with age, and that decline really is linked to the way cells break down over time. The trouble starts when "linked to" gets quietly upgraded to "fixes." This article is the biology explainer: what NAD+ is, why it falls, what that does to your cells, and how to think clearly about the booster landscape.
What NAD+ actually is
NAD+ — nicotinamide adenine dinucleotide — is a coenzyme found in every living cell. The simplest way to picture it is as a rechargeable electron shuttle. In the reactions that turn food into usable energy, NAD+ grabs electrons (becoming NADH), ferries them to the mitochondria, drops them off to help generate ATP, and cycles back as NAD+ to do it again. That redox role alone makes it indispensable: without enough NAD+, the basic machinery of metabolism slows down.
But NAD+ has a second job that is arguably more interesting for aging. It is also a required fuel — literally consumed — by a set of enzymes that maintain and repair the cell. According to PubMed, a comprehensive review in Nature Reviews Molecular Cell Biology describes how NAD+ serves as an essential cofactor for non-redox enzymes including the sirtuins, the poly(ADP-ribose) polymerases (PARPs), and CD38, and how through them NAD+ touches DNA repair, chromatin remodeling, cellular senescence, immune-cell function and metabolic signaling.[1] In other words, NAD+ is not just an energy carrier; it is the currency these repair-and-maintenance crews spend to do their work.
The sirtuins, PARPs and the DNA-repair connection
The sirtuins are the enzymes that made NAD+ famous in longevity circles. They strip chemical tags off proteins and DNA-packaging histones, and in doing so they help regulate metabolism, inflammation, mitochondrial biogenesis and the stress responses that keep cells healthy. The catch is that sirtuins cannot function without NAD+ — it is their obligatory cofactor. When NAD+ runs low, sirtuin activity falls with it, regardless of how many sirtuins the cell has.
The PARPs are the cell's DNA-damage first responders. When your genome takes a hit — and it takes thousands of hits a day — PARP enzymes rush in and consume large amounts of NAD+ to flag and coordinate the repair. This sets up a quiet competition: every time PARPs fire to fix DNA, they are spending the same NAD+ that sirtuins and mitochondria need. According to PubMed, a review of neurodegeneration in accelerated-aging disorders details exactly this dynamic, showing how nuclear DNA damage drives PARP1 hyperactivation, which depletes NAD+ and downstream metabolites and impairs mitochondrial function — and how restoring those metabolites can reverse some of the damage in models.[2] That is the mechanistic heart of why people care about NAD+: it sits at the intersection of energy, repair and the enzymes that govern healthy aging.
Why NAD+ declines with age
Here is the fact that launched a thousand supplements: NAD+ levels fall as we get older. According to PubMed, a review in Experimental Gerontology by McReynolds, Chellappa and Baur surveys the evidence that NAD+ concentrations decline in the tissues of aged animals and examines the candidate mechanisms — increased consumption, decreased synthesis, or shifts in the cellular makeup of tissues — while noting that direct human data remain limited and that better tools are still needed to pin down which tissues and compartments are most affected.[3] That last caveat matters: the decline is real, but it is more nuanced than the influencer version, in which NAD+ simply "runs out."
So why does it fall? The most compelling recent answer points less at a factory that stops making NAD+ and more at consumers who burn through it faster. According to PubMed, an isotope-tracing study in Cell Systems found that in aged mice, tissue NAD+ dropped modestly (a median decrease of roughly 30%), yet the rate of NAD+ production was largely maintained — the smaller pool simply turned over faster, consistent with more active NAD+-consuming enzymes; calorie restriction partly blunted the decline by reducing consumption.[4] This reframes the whole problem. If aging tissues are not failing to make NAD+ so much as spending it too fast, then the interesting target may be the spenders.
CD38: the NAD+ vacuum cleaner of an aging body
Among those spenders, one enzyme keeps coming up: CD38. It is an NAD+-consuming enzyme found largely on immune cells, and its activity rises with age — in step with the chronic, low-grade inflammation ("inflammaging") that accompanies getting older. According to PubMed, a review in Mechanisms of Ageing and Development frames age-related NAD+ loss explicitly as a balance problem between biosynthesis and consumption, describing how reduced levels of the rate-limiting synthesis enzyme NAMPT combine with increased activation of the NAD+-consuming enzymes PARPs and CD38 to drain tissue NAD+ — and how restoring NAD+ can halt or reverse some age-related disease in models.[5] The picture that emerges is a tug-of-war: on one side, production machinery that slows a little; on the other, a growing crowd of NAD+ consumers — PARPs responding to accumulating DNA damage, and CD38 ramping up with age-related inflammation. NAD+ decline is the net result.
What the decline does to cells
Follow the chain and the downstream consequences become intuitive. Less NAD+ means mitochondria have less of the shuttle they need to run oxidative metabolism efficiently — energy production gets less crisp. Less NAD+ means sirtuins, which depend on it, work less, loosening the regulation of metabolism, inflammation and mitochondrial upkeep. Less NAD+ means PARPs have less fuel to coordinate DNA repair even as damage accumulates. None of these failures is dramatic on its own; together, over decades, they map neatly onto the hallmarks of cellular aging — mitochondrial dysfunction, genomic instability, senescence and chronic inflammation — which is precisely why NAD+ has become such a magnet for longevity research.[1]
The booster landscape: a tour, not a verdict
If NAD+ falls and that decline drives cellular wear, the obvious move is to put it back. You cannot just swallow NAD+ itself efficiently, so the field uses precursors — building blocks the body converts into NAD+. The two stars are NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside).
In animals, the case is genuinely impressive. According to PubMed, a landmark 12-month study in Cell Metabolism gave normally aging mice oral NMN and found it was quickly used to make NAD+ in tissues and "effectively mitigated age-associated physiological decline" — suppressing age-related weight gain, improving insulin sensitivity and energy metabolism, and enhancing mitochondrial function in skeletal muscle, with no obvious toxicity.[6] Results like this are the reason the whole industry exists.
The honest part is what happens when you move from mice to people. Human trials consistently confirm the first step — that oral precursors raise NAD+. According to PubMed, a randomized, double-blind, placebo-controlled trial in healthy overweight adults found that nicotinamide riboside dose-dependently and significantly increased whole-blood NAD+ — by 22%, 51% and 142% at 100, 300 and 1,000 mg/day — with no serious adverse effects.[7] The biochemistry works. But raising a blood marker is not the same as slowing aging, and that is where the story gets harder. According to PubMed, a randomized placebo-controlled trial of NR in older adults with mild cognitive impairment confirmed the precursor raised blood NAD+ 2.6-fold and was well tolerated, yet cognition (the actual outcome that matters) remained unchanged over the study.[8] That gap — robust on the surrogate, quiet on the real-world endpoint — is the defining feature of the human NAD+ literature so far.
This is the line between this article and the next one. The biology of why you might want more NAD+ is strong. The question of whether NMN or NR pills meaningfully improve human health in practice is a separate, more demanding question — and the answer there is "promising but unproven." For what the human supplement trials actually found — the doses, the endpoints and the verdict — see our NMN and NAD+ review.
The bottom line
NAD+ deserves its reputation as one of the most important molecules in cell biology. It runs your energy metabolism, fuels your DNA-repair enzymes, and switches on the sirtuins. Its decline with age is real, and the best current evidence suggests the decline is driven as much by accelerating consumption — PARPs answering DNA damage, CD38 rising with inflammation — as by any failure to produce it. That makes NAD+ a deeply logical place to look for longevity interventions. It is also exactly why it gets oversold: a compelling mechanism is not the same as a proven therapy in humans. The interventions we already know support NAD+ and the same pathways — regular exercise, not overeating, and good sleep — remain the highest-confidence moves, and they cost nothing.
Common questions
What is NAD+ and why does it matter?
NAD+, nicotinamide adenine dinucleotide, is a coenzyme in every living cell. It acts as a rechargeable electron shuttle that helps turn food into energy, and it is the fuel spent by repair enzymes including the sirtuins, PARPs and CD38. Through them it touches DNA repair, metabolism and the enzymes that govern healthy aging.
Why does NAD+ decline with age?
Tissue NAD+ falls with age, and the best recent evidence points more at faster consumption than failing production. An isotope-tracing study found aged mice kept making NAD+ but burned through it faster. PARPs spend it answering DNA damage and CD38 rises with age-related inflammation, while production enzymes like NAMPT slip a little.
Do NAD+ boosters like NMN and NR work?
They reliably raise blood NAD+ in people. One trial showed nicotinamide riboside increased whole-blood NAD+ dose-dependently, up to 142 percent. But raising that marker is not the same as slowing aging: a trial in older adults with mild cognitive impairment lifted NAD+ 2.6-fold yet cognition stayed unchanged. Promising but unproven.